Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone Receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Testing effectiveness (Phase 2)Ended earlyNCT00138125
What this trial is testing

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Translational Oncology Research International 2
Testing effectiveness (Phase 2)Ended earlyNCT00549822
What this trial is testing

Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 3
Testing effectiveness (Phase 2)Looking for participantsNCT05816655
What this trial is testing

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Korea University Guro Hospital 202
Large-scale testing (Phase 3)Active Not RecruitingNCT04711252
What this trial is testing

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 1,370
Testing effectiveness (Phase 2)Study completedNCT03007992
What this trial is testing

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Johannes Gutenberg University Mainz 9
Testing effectiveness (Phase 2)Ended earlyNCT00722072
What this trial is testing

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
OHSU Knight Cancer Institute 12
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Testing effectiveness (Phase 2)Study completedNCT01797120
What this trial is testing

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Who this might be right for
Metastatic Breast Cancer
PrECOG, LLC. 131
Not applicableLooking for participantsNCT05795335
What this trial is testing

CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
RenJi Hospital 172
Not applicableStudy completedNCT06705504
What this trial is testing

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Novartis 435
Testing effectiveness (Phase 2)Study completedNCT02035813
What this trial is testing

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Who this might be right for
HER2-negative and Hormone-receptor Positive Metastatic Breast CancerHER2-negative Circulating Tumor CellsPostmenopausal Female Patients
Prof. Wolfgang Janni 116
Testing effectiveness (Phase 2)Ended earlyNCT04142060
What this trial is testing

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 34
Not applicableStudy completedNCT00638391
What this trial is testing

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,600
Early research (Phase 1)Study completedNCT02058381
What this trial is testing

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Pre-menopausal Breast CancerPI3K Pathway Inhibition
Novartis Pharmaceuticals 40
Large-scale testing (Phase 3)Study completedNCT01958021
What this trial is testing

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Novartis Pharmaceuticals 668
Testing effectiveness (Phase 2)Ended earlyNCT03241810
What this trial is testing

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Elevation Oncology 22
Testing effectiveness (Phase 2)WithdrawnNCT00217659
What this trial is testing

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network
Large-scale testing (Phase 3)UnknownNCT01710605
What this trial is testing

Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers

Who this might be right for
Ductal Infiltrating Metastatic Breast CancerHormone-receptors Positive Breast Cancer
Institut Curie 800
Large-scale testing (Phase 3)Study completedNCT03462251
What this trial is testing

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Who this might be right for
Breast CancerHormone Receptor Positive TumorHER 2 Negative Breast Cancer
iOMEDICO AG 41
Next Page